))
Using Real-World Studies to Compare DMTs in MS
Manage episode 407345651 series 3559522
Content provided by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by European Committee for Treatment and Research in Multiple Sclerosis, The European Committee for Treatment, and Research in Multiple Sclerosis or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, and Maria Pia Sormani, Professor of Biostatistics at the University of Genoa, discuss the use of real-world data to compare disease-modifying treatments (DMTs) in multiple sclerosis, including the advantages and limitations of randomised control trials and observational studies. Hosted by Alan Thompson, Editor-in-Chief of the MS Journal and Professor at University College London.
34 episodes
Share
